PT1206274E - Utilização de inibidores de interleucina-18 para inibir a metástase de tumores. - Google Patents

Utilização de inibidores de interleucina-18 para inibir a metástase de tumores. Download PDF

Info

Publication number
PT1206274E
PT1206274E PT00944201T PT00944201T PT1206274E PT 1206274 E PT1206274 E PT 1206274E PT 00944201 T PT00944201 T PT 00944201T PT 00944201 T PT00944201 T PT 00944201T PT 1206274 E PT1206274 E PT 1206274E
Authority
PT
Portugal
Prior art keywords
cells
hse
adhesion
tnf
production
Prior art date
Application number
PT00944201T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of PT1206274E publication Critical patent/PT1206274E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT00944201T 1999-07-22 2000-07-17 Utilização de inibidores de interleucina-18 para inibir a metástase de tumores. PT1206274E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
PT1206274E true PT1206274E (pt) 2007-07-06

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00944201T PT1206274E (pt) 1999-07-22 2000-07-17 Utilização de inibidores de interleucina-18 para inibir a metástase de tumores.

Country Status (31)

Country Link
US (1) US7741276B2 (enExample)
EP (1) EP1206274B1 (enExample)
JP (1) JP4827352B2 (enExample)
KR (1) KR100682219B1 (enExample)
CN (1) CN1173736C (enExample)
AR (1) AR024907A1 (enExample)
AT (1) ATE363288T1 (enExample)
AU (1) AU782478B2 (enExample)
BG (1) BG65800B1 (enExample)
BR (1) BR0012675A (enExample)
CA (1) CA2380216C (enExample)
CY (1) CY1107932T1 (enExample)
CZ (1) CZ302114B6 (enExample)
DE (2) DE60035049T2 (enExample)
DK (1) DK1206274T3 (enExample)
EA (1) EA005419B1 (enExample)
EE (1) EE04838B1 (enExample)
ES (1) ES2186596T3 (enExample)
HK (1) HK1048248B (enExample)
HU (1) HU228780B1 (enExample)
IL (2) IL131047A0 (enExample)
MX (1) MXPA02000838A (enExample)
NO (1) NO329827B1 (enExample)
NZ (1) NZ516535A (enExample)
PL (1) PL202477B1 (enExample)
PT (1) PT1206274E (enExample)
SK (1) SK287522B6 (enExample)
TR (1) TR200200169T2 (enExample)
UA (1) UA73745C2 (enExample)
WO (1) WO2001007480A2 (enExample)
ZA (1) ZA200200390B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
MXPA03010575A (es) * 2001-05-16 2005-03-07 Yeda Res & Dev Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis.
RU2225720C1 (ru) * 2002-08-12 2004-03-20 Научно-исследовательский институт онкологии Томского научного центра СО РАМН Средство, повышающее противоопухолевую и антиметастатическую активность циклофосфана
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
PE20251671A1 (es) 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
WO2024148243A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2732546B2 (ja) * 1992-09-02 1998-03-30 アイシス・ファーマシューティカルス・インコーポレーテッド 細胞接着のオリゴヌクレオチド調節
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
CN1173736C (zh) 2004-11-03
JP2003505472A (ja) 2003-02-12
PL202477B1 (pl) 2009-06-30
CA2380216A1 (en) 2001-02-01
NO20020153D0 (no) 2002-01-11
HUP0202107A3 (en) 2005-01-28
EP1206274B1 (en) 2007-05-30
ES2186596T3 (es) 2007-11-16
ZA200200390B (en) 2003-04-30
JP4827352B2 (ja) 2011-11-30
NO329827B1 (no) 2011-01-03
PL353732A1 (en) 2003-12-01
DK1206274T3 (da) 2007-08-13
KR20020027493A (ko) 2002-04-13
DE60035049D1 (de) 2007-07-12
AU5843200A (en) 2001-02-13
ES2186596T1 (es) 2003-05-16
EE200200032A (et) 2003-02-17
TR200200169T2 (tr) 2002-06-21
US20080003216A1 (en) 2008-01-03
DE60035049T2 (de) 2007-09-27
AU782478B2 (en) 2005-08-04
KR100682219B1 (ko) 2007-02-12
SK287522B6 (sk) 2011-01-04
CY1107932T1 (el) 2013-09-04
EP1206274A2 (en) 2002-05-22
HK1048248A1 (en) 2003-03-28
BG65800B1 (bg) 2009-12-31
US7741276B2 (en) 2010-06-22
NZ516535A (en) 2004-04-30
BRPI0012675B8 (enExample) 2021-05-25
HK1048248B (zh) 2005-04-22
EE04838B1 (et) 2007-06-15
EA005419B1 (ru) 2005-02-24
WO2001007480A2 (en) 2001-02-01
CA2380216C (en) 2012-01-31
ATE363288T1 (de) 2007-06-15
BG106311A (en) 2002-08-30
MXPA02000838A (es) 2002-07-30
BR0012675A (pt) 2002-04-09
DE1206274T1 (de) 2002-11-14
IL131047A0 (en) 2001-01-28
SK882002A3 (en) 2002-07-02
HU228780B1 (en) 2013-05-28
UA73745C2 (en) 2005-09-15
AR024907A1 (es) 2002-10-30
HUP0202107A2 (en) 2002-10-28
CN1364086A (zh) 2002-08-14
IL147675A (en) 2009-05-04
CZ2002195A3 (cs) 2002-06-12
CZ302114B6 (cs) 2010-10-20
WO2001007480A3 (en) 2001-05-10
BRPI0012675B1 (pt) 2001-02-01
NO20020153L (no) 2002-03-11
EA200200189A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Dinarello Interleukin-18
ES2379977T3 (es) Proteínas de fusión de taci-inmunoglobulina
JPH07509223A (ja) インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH10511266A (ja) ヒト・インターロイキン−１１受容体
EP1025229A1 (en) Chemokines with amino-terminal modifications
Tada et al. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1
JP3226918B2 (ja) 腫瘍壊死因子とインターロイキン−４の相乗作用
JP2863265B2 (ja) インターロイキン１インヒビター
JPH0725785A (ja) インターロイキン−６の医薬組成物
KR101769122B1 (ko) 케모카인 발현 조절제
US20040063132A1 (en) UMLR polypeptides
Ryffel et al. Correction of the TNF‐LTα‐Deficient Phenotype by Bone Marrow Transplantation
Medvedev et al. A Non‐Competitive P55 TNF Receptor Antibody Enhances the Specific Activity of Lymphotoxin‐α
Yu Molecular characterization and regulation of IL-1 receptors in bovine leukocytes
Jiang Increased core temperature during febrile disease modulates cytokine expression, enhances host defense, and improves survival in bacterial infection
Dinarello IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1